Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activations

Canadian Cancer Trials Group CLC.2 (Alliance A041202) - A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL) - was centrally activated February 5, 2015.

The purpose of the study is to determine whether progression-free survival is superior after therapy with bendamustine in combination with rituximab, ibrutinib alone, or ibrutinib in combination with rituximab in patients age 65 or older with previously untreated CLL. Total sample size is 523 patients.

Canadian Cancer Trials Group IND.219 - A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Cisplatin Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-squamous Non-Small Cell Lung Cancer - was centrally activated February 5, 2015.

This is an open-label, randomized phase II clinical study of selumetinib (intermittent or continuous) in patients with advanced or metastatic KRAS wildtype or unknown KRAS status, non-squamous non-small cell lung cancer (NSCLC) who are receiving pemetrexed/cisplatin as a first line palliative treatment. The total sample size is 140 patients.


Canadian Cancer Trials Group PR.17 (ANZUP 1304) - Randomized Phase III Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET - was centrally activated February 2, 2015.

The purpose of the trial is to determine the effectiveness of enzalutamide versus a conventional NSAA when combined with a luteinising hormone releasing hormone analogue or surgical castration, as first line androgen deprivation therapy. The overall trial sample size is 1100 patients.